179 related articles for article (PubMed ID: 18957967)
1. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
2. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Popat S; Smith IE
Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
4. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
Gianni L
Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
[No Abstract] [Full Text] [Related]
5. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
6. [Therapy concept: herceptin with anthracyclines].
Untch M
Onkologie; 2002 Dec; 25 Suppl 5():19-21; discussion 21. PubMed ID: 23573616
[No Abstract] [Full Text] [Related]
7. [Cardiac prevention: the oncologic point of view].
Gligorov J; Debourdeau P; Arsovski O; Lotz JP
Bull Cancer; 2004 Nov; 91 Suppl 3():192-200. PubMed ID: 15899627
[TBL] [Abstract][Full Text] [Related]
8. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
Ewer MS; Ewer SM
J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
[No Abstract] [Full Text] [Related]
9. Trastuzumab and cardiotoxicity: weighing the risks.
Wong SF
Am J Health Syst Pharm; 2006 Mar; 63(6):525. PubMed ID: 16522888
[No Abstract] [Full Text] [Related]
10. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
11. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
13. [Breast conserving surgery after preoperative chemotherapy].
Miyaguni T; Murayama S; Nishimaki T
Nihon Rinsho; 2007 Jun; 65 Suppl 6():445-8. PubMed ID: 17682191
[No Abstract] [Full Text] [Related]
14. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
Sukel MP; Breekveldt-Postma NS; Erkens JA; van der Linden PD; Beiderbeck AB; Coebergh JW; Herings RM
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):125-34. PubMed ID: 18058835
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
Montemurro F; Redana S; Valabrega G; Martinello R; Aglietta M; Palmiero R
J Clin Oncol; 2008 Apr; 26(12):2052-3; author reply 2053-4. PubMed ID: 18421060
[No Abstract] [Full Text] [Related]
17. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
18. Cardiac risks in multimodal breast cancer treatment.
Budach W
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
[No Abstract] [Full Text] [Related]
19. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Brower V
J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
[No Abstract] [Full Text] [Related]
20. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
[Next] [New Search]